Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on September 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO Geoffrey Parker retiring from Allogene in all capacities effective November 6, 2026.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Geoffrey Parker retiring from Allogene in all capacities effective November 6, 2026
- Principal financial officer transition creates near-term succession and execution risk
- Notice submitted August 31, 2026, with approximately two-month transition period
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.